Evidence map›Paper›PMID 41249746›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026

Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study).

Yoko Iwata, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Genki Sato, Atsuhito Saiki, Takamasa Ichijyo, Nobuyuki Sato, Tadamasa Ohashi, Takahisa Hirose and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoko Iwata *Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Fukumi Yoshikawa *Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Manabu SaitoDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Ayako FuchigamiDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Genki SatoDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Atsuhito SaikiCenter of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan.
Takamasa IchijyoSasiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa, 230-8765, Japan.
Nobuyuki SatoSato Medical Clinic, 5-9-7 Omori-Nishi, Ota-ku, Tokyo, 143-0015, Japan.
Tadamasa OhashiKamata Diabetes Clinic, 4-29-2 Kamata, Ota-ku, Tokyo, 144-0052, Japan.
Takahisa HiroseDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Hiroshi UchinoDivision of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Graduate School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. h.uchino@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0001-9282-918X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOnce-weekly semaglutide has proven to be a safe and effective treatment for type 2 diabetes; however, clinical trial data on Asian populations are limited, warranting real-world data (RWD). In this study we assessed the effectiveness and safety of semaglutide in Japanese patients with type 2 diabetes using RWD.

methodsA retrospective analysis was conducted at five diabetes centers in Japan between December 2019 and June 2022. Changes in hemoglobin A1C (HbA1c), body weight (BW), lipid parameters, liver/kidney function, and adverse events were assessed over 52 weeks. Subgroup analyses were stratified by glucagon-like peptide-1 receptor agonist (GLP-1RA)-naïve users versus prior GLP-1RA users (GLP-1RA switch group), baseline body mass index (BMI) (< 30 or ≥ 30 kg/m

resultsOf the 503 patients included in the study, 270 (mean age 53 years; 61.8% men; mean duration of diabetes 10.7 years) were included in the per-protocol analysis. Mean (± standard deviation) baseline HbA1c and BMI were 8.1 ± 1.5% and 31.7 ± 6.2 kg/m

conclusionsOnce-weekly semaglutide improved glycemic control, BW, lipid profiles, and liver function in Japanese patients with type 2 diabetes in RWD and subgroup analyses, supporting a broad effectiveness range. The rate of gastrointestinal adverse events in the RWD was comparable to that in prospective clinical studies. REGISTRATION: University hospital Medical Information Network Clinical Trial Registry No.: UMIN000050499).

Indexed as

Adverse eventsBody mass indexJapanese patients semaglutideReal-world dataType 2 diabetes

Identifiers

PMID41249746
PMCPMC12847525

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.